BTG's International Asia unit contributed $11m to $16.8m series B round, taking a 10% stake in the medical isotopes developer.

China-based radioactive medicine developer Chengdu New Radiomedicine Technology (CNRT)  has raised RMB116m ($16.8m) in a series B round led by BTG International Asia, a subsidiary of healthcare provider BTG.

The round was filled out by commitments from investment firms Hangzhou Ruizhao and returning investor Ningbo Zhongchao Investment. BTG invested approximately $11m in the round for a 10% stake in the business.

Founded in 2016, CNRT is developing medical isotopes designed to diagnose and treat several forms of cancer.

BTG will…